Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adults With Ulcerative Colitis Clear all
Recruiting Phase 2 Interventional

Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis

NCT04373473
View directory record Official record
Conditions
Adults With Ulcerative Colitis
Interventions
PRIM-DJ2727, Placebos
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

NCT06867094
View directory record Official record
Conditions
Colitis Ulcerative
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

NCT07697456
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
Risankizumab, Trosunilimab, ABBV-701
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
22
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Terminated Not applicable Interventional

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI)

NCT00360022
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
Interventions
Joint visits
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 1, 2026, 10:03 PM EDT
Terminated Early Phase 1 Interventional

Serum Bovine Immunoglobulin (SBI) in Children and Young Adults With Inflammatory Bowel Disease (IBD)

NCT04223518
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Serum bovine immunoglobulin, Placebo
Dietary Supplement
Lead sponsor
Monisha Hitesh Shah
Other
Eligibility
6 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Not applicable Interventional Results available

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

NCT00791557
View directory record Official record
Conditions
Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

NCT06095128
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab, Tofacitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Dothan, Alabama • Sun City, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 3 Interventional

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086
View directory record Official record
Conditions
Ulcerative Colitis, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

NCT01124149
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX mesalamine/ mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis

NCT05570006
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABBV-668
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
18
States / cities
Chula Vista, California • Maitland, Florida • Margate, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 1, 2026, 10:03 PM EDT
Terminated Phase 1 Interventional Results available

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

NCT03169894
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
MDGN-002
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Hialeah, Florida • New Port Richey, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

NCT04090411
View directory record Official record
Conditions
Moderate to Severe Ulcerative Colitis
Interventions
Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W, Induction- Placebo SC Q4W, Chronic- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Dothan, Alabama • Little Rock, Arkansas • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Not applicable Interventional

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

NCT04508413
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
KB295
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Sep 1, 2026, 10:03 PM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

NCT01694485
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Abrilumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
25
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

NCT02914522
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Filgotinib, PTM filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
61
States / cities
Dothan, Alabama • Scottsdale, Arizona • Long Beach, California + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 1, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

NCT04130919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044
View directory record Official record
Conditions
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
LY4268989, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
52
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Completed Phase 4 Interventional

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

NCT06346288
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Breast Milk Sampling, Risankizumab
Procedure · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183
View directory record Official record
Conditions
Colitis Ulcerative, Ulcerative Colitis
Interventions
MK-8690, Placebo
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Anaheim, California • Coronado, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 10:03 PM EDT
Recruiting No phase listed Observational

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

NCT06398626
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
26
States / cities
Mesa, Arizona • La Jolla, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 1, 2026, 10:03 PM EDT